AU

Darren Ross Jones

This inventor holds 0 USPTO granted patents, plus 3 CIPO patents.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Darren Ross Jones. Retrieved from https://idiyas.com/inventor/darren-ross-jones-t1btrkfi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Loading Chart...

Title: The Innovations of Darren Ross Jones

Introduction

Darren Ross Jones is an accomplished inventor based in Australia. He has made significant contributions to the field of medical science, particularly in the diagnosis and treatment of B-cell disorders. His work focuses on innovative approaches to combat diseases such as multiple myeloma.

Latest Patents

Darren holds a patent titled "Target For B-Cell Disorders." This invention relates to the diagnosis and treatment of B-cell disorders, specifically targeting multiple myeloma. The patent emphasizes the use of ligands that bind to free lambda light chains expressed on the surface of lymphoid cancer cells, offering a novel method for treatment.

Career Highlights

Darren is currently employed at Haemalogix Pty. Ltd., where he continues to develop groundbreaking solutions in the medical field. His expertise and dedication to research have positioned him as a key figure in the fight against B-cell disorders.

Collaborations

Darren collaborates with Parisa Asvadi, working together to advance their research and innovations in the medical sector.

Conclusion

Darren Ross Jones is a notable inventor whose work in the treatment of B-cell disorders showcases his commitment to improving healthcare outcomes. His innovative approaches and collaborations continue to pave the way for advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…